China Accepts First Line HER2 ADC Filing

Company Jiangsu Hengrui; Suzhou Shengdiya Event Type Regulatory filing acceptance with priority review (China) Modality HER2-directed antibody-drug conjugate Asset Rezetecan trastuzumab (SHR-A1811) Target HER2 Disease Area First-line HER2-positive locally advanced or metastatic breast cancer Summary China-originated regulatory signal: Hengrui disclosed on 29 October that NMPA…